1 October 2018 - A novel subcutaneous auto-injector product approved for once weekly at-home therapy.

Antares Pharma today announced the approval of Xyosted (testosterone enanthate) injection by the U.S. FDA. Xyosted is the first FDA approved subcutaneous testosterone enanthate product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable QuickShot auto injector. 

Xyosted has been approved in three dosage strengths, 50 mg, 75 mg and 100 mg and is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

Read Antares Pharma press release